Theranexus Liquidity Contract Half-Year Review

Theranexus, a biopharmaceutical company focused on rare neurological diseases, has published its half-year report regarding its liquidity contract with Portzamparc. As of December 31, 2025, 37,142 THX Pharma shares and €42,872.78 were available in the liquidity account. By comparison, the balance sheet as of June 30, 2025, showed 41,770 shares and €31,202.02.

Since the contract's inception in 2018, the initial portfolio consisted of 14,114 shares and €95,788.55. A significant withdrawal of €50,000 was made in March 2025. For the second half of 2025, 183,053 shares were purchased for a total of €401,102.55, while 187,681 shares were sold for €412,773.31.